SLC11A2 and Parkinson disease: The pathological increase in DMT1 levels has been found in neurodegenerative disorders, such as Parkinson’s disease (PD; Salazar et al., 2008; Zhang et al., 2009, 2017; Jiang et al., 2010; Xu et al., 2010; Du et al., 2016) and AD (Zheng et al., 2009; Xie et al., 2012).